CG

In the past six months (March-September 2026), Carlyle's stock experienced a 31% year-to-date decline and hit a new 52-week low of $39.16 to $39.58 in September 2026. Q1 2026 earnings (May 7, 2026) showed strong financial results with $300 million in fee-related earnings and $13 billion in new capital attracted. Q2 2026 earnings (August 5, 2026) exceeded analysts' expectations with an adjusted EPS of $1.07 and $1.12 billion in revenue, driven by record fee-related earnings, high distributable earnings, and $17 billion in fundraising, despite a year-over-year decline in GAAP net income and revenue. Carlyle has strong fundraising momentum, attracting $17 billion in Q2 2026 and $56 billion over the past year, pushing AUM to a record $485 billion, and anticipates a 'supercycle' in private markets. On September 24, 2026, Piper Sandler initiated coverage with an 'Overweight' rating and a $54.00 price target, though overall analyst sentiment is mixed with an average 'Hold' rating and a $59.31 consensus target price. Insider selling has been notable, totaling $17,096,000 over three months, with co-founder David Rubenstein also selling shares. Market concerns include fears over private credit, slower capital raising for new funds, and higher global interest rates.